Neogenomics
NEO
Neogenomics (NEO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.05
- EPS estimate
- $0.03
- EPS surprise
- +49.25%
- Revenue surprise
- +2.40%
- Revenue
- $201.7M
- Revenue estimate
- $196.9M
- Reported
- Jul 28, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 28, 2026 | $0.03 | $0.05 | +49.25% | $201.7M | SEC |
| Q1 2026 | Apr 28, 2026 | $0.01 | $0.01 | +72.41% | $186.7M | SEC |
| Q4 2025 | Feb 17, 2026 | $0.04 | $0.06 | +47.78% | $190.2M | SEC |
| Q3 2025 | Oct 28, 2025 | $0.02 | $0.03 | +46.34% | $187.8M | SEC |
| Q2 2025 | Jul 29, 2025 | $0.02 | $0.03 | +29.31% | $181.3M | SEC |
| Q1 2025 | Apr 29, 2025 | −$0.01 | $0.00 | +100.00% | $168.0M | SEC |
| Q4 2024 | Feb 18, 2025 | $0.03 | $0.04 | +38.89% | $172.0M | SEC |
| Q3 2024 | Nov 5, 2024 | $0.01 | $0.05 | +306.50% | $167.8M | SEC |
| Q2 2024 | Jul 29, 2024 | −$0.00 | $0.03 | +1067.74% | $164.5M | SEC |
| Q1 2024 | Apr 30, 2024 | −$0.04 | −$0.02 | +49.62% | $156.2M | SEC |
| Q4 2023 | Feb 20, 2024 | −$0.02 | $0.03 | +221.46% | $155.6M | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.07 | $0.00 | +100.00% | $152.0M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.11 | −$0.05 | +56.18% | $146.9M | SEC |
| Q1 2023 | May 8, 2023 | −$0.14 | −$0.09 | +35.44% | $137.2M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.16 | −$0.06 | +63.55% | $138.7M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.21 | −$0.14 | +32.10% | $128.8M | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.23 | −$0.16 | +31.77% | $125.1M | SEC |
| Q1 2022 | Apr 27, 2022 | −$0.24 | −$0.20 | +15.82% | $117.2M | SEC |
| Q4 2021 | Feb 23, 2022 | −$0.15 | −$0.14 | +7.22% | $125.7M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.09 | −$0.08 | +11.11% | $121.3M | SEC |
Quarterly revenue
Frequently asked questions
When did Neogenomics (NEO) last report earnings?
Neogenomics last reported on Jul 28, 2026, covering fiscal Q2 2026.
Did NEO beat earnings estimates?
Yes. Neogenomics reported EPS of $0.05 for Q2 2026 against a $0.03 estimate — a 49.25% beat.
How much revenue did NEO report last quarter?
Neogenomics reported $201.7M in revenue for Q2 2026, against a consensus estimate of $196.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.